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INTRODUCTION
As a potential pathogen of zoonosis, Baylisascaris transfuga is 
a ubiquitous gastrointestinal nematode of almost all species of 
bears, including giant panda Ailuropoda melanoleuca, Malayan 
sun bears Helarctos malayanus, sloth bears Melursus ursinus, 
American black bears Ursus americanus, brown bears Ursus arc-
tos, polar bears Ursus maritimus, Asiatic black bears Selenarctos 
thibetanus, and Andean bears Tremarctos ornatus. Within as few 
as 2 weeks, B. transfuga eggs, which are evacuated along with 
feces of bears, can not only mature to infective larvae, but also 
remain viable in zoo environment for up to 5 years. Under 
laboratory conditions, B. transfuga eggs retain their infectivity 
for at least 15 months. Herbaceous plant, soil, and water 
sources contaminated by B. transfuga eggs are the major infec-
tive agent of this zoonosis. B. transfuga can impact natural host 
survival and reproduction directly through pathologic effects 
and indirectly by reducing host condition. Furthermore, it can 
give rise to lethal larva migrans syndromes in occasional hosts, 
such as alternative livestock, free ranging domestic fowls and 
humans [1]. 
Due to its widespread transmission among bear popula-
tions, it is more possible for people who get in touch with 
bears and their feces frequently, such as zookeepers and ani-
mal trainers, to be infected. In certain countries, some cases in-
dicated that bears were implicated in human visceral larva mi-
grans by B. transfuga [2]. According to previous studies on lar-
val migration of Baylisascaris in mice, following oral infection 
with infective eggs, most of the larvae hatched in the gastroin-
testinal tract and remained in the intestinal wall, while others 
migrated though the liver and lungs to reach other organs, in-
cluding the brain, and mostly the musculature [3,4]. Hence, 
infective larvae can not complete the whole growth cycle in 
the incidental host, but can invade into central nervous system 
(CNS) and implicate in irreversible nervous larvae migrans 
(NLM). Otherwise, Papini [5] experimentally inoculated 
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chickens with B. transfuga infected eggs, and considered that 
the larvae may be able to penetrate the liver, lungs, carcass, and 
brain of infected chickens. However, a great number of larvae 
accumulated in the liver [5]. In most cases, within 2 weeks, 
Baylisascaris larvae can be encapsulated by granulation tissues, 
so that they tend to settle and/or trapped in muscles or other 
tissues. Becoming encapsulated, larvae can survive in tissues of 
mice for several months, even after freezing and putrefaction 
[3]. In experimentally infected monkeys and rats, Baylisascaris 
procyonis larval granulomas, often visible grossly, were abun-
dant in many organs and tissues, including the liver, lungs, 
heart, intestinal wall, skeletal muscles, brain, and eyes [4].
Several anthelmintics have been proved to be effective aga-
inst adult Baylisascaris in definitive hosts, including racco-ons, 
skunks, dogs, and bears. Bauer and Gey [6] treated raccoons 
infected with B. procyonis with ivermectin (1 mg/kg) orally, 
found out that 24 adult raccoon roundworms were expelled in 
the feces on day 2 post-treatment [6]. No worms were observ-
ed in corpses on day 7 post-treatment. In addition, another 5 
anthelmintics, including pyrantel embonate, moxidectin, al-
bendazole, fenbendazole, and flubendazole, were considered 
useful against B. procyonis, based on their studies. However, 
due to the lack of early diagnosis, rare anthelmintics have been 
proved to be effective enough to control Baylisascaris larva mi-
grans [7,8]. 
 Ivermectin, a member of the macrocyclic lactone endecto-
cides, is a broad-spectrum anthelmintic. It has been successful-
ly used to control a wide range of gastrointestinal helminths 
in livestock [9,10]. Levamisole also is used in helminth control 
programmes with good results and has been frequently used 
in clinical application. 
However, due to the fact that once larvae have entered CNS, 
significant neurological damage quickly occurs, for the most 
part, irreversible. Unfortunately, this is the time when infection 
is still asymptomatic and likely to be unrecognized [4,7]. Pap-
ini et al. [8] treated mice infected with 3,000 B. transfuga eggs 
with a large dose of ivermectin (2 mg/kg) subcutaneously, and 
supported that, to a certain extent, ivermectin was useful in 
limiting the nervous migratory activity of larvae, based on the 
highest percentage reduction of larvae in brain (66.7%). Nev-
ertheless, as far as we know, few have been reported on the 
comparative efficacy of levamisole and ivermectin against B. 
transfuga larvae, and whether ivermectin could produce more 
marked effects on their migratory activity in other organs of 
mice. Therefore, the objective of the present trial was to com-
pare the efficacy of ivermectin and levamisole against B. transf-
uga migrating larvae and encapsulated larvae in mice. 
MATERIALS AND METHODS
Baylisascaris transfuga eggs and animals
In order to compare the efficacy of ivermectin and levami-
sole for control of B. transfuga larvae in mice and whether iver-
mectin offered advantages to limit B. transfuga larval migration 
in various organs (not only the brain), Baylisascaris transfuga 
adult females were recovered from a captive polar bear living 
in the Chengdu Zoological Garden, Chengdu, China. Eggs 
were obtained and cultured as described by Papini and Casa-
rosa [1].
Sixty BALB/c mice of both sexes, aged 4 weeks and weighing 
20-25 g each, were obtained from Laboratory Animal Center 
of Sichuan University (Chengdu, China), and randomly assig-
ned into 6 groups (A-F). Each group contained 10 mice, males 
and females. Institutional Ethical and Animal Care guidelines 
were adhered to during the sampling exercise, and all proce-
dures were carried out in accordance with the Guide for the 
Care and Use of Laboratory Animals. 
During the experimental period, the different sexes were 
kept separately, and maintained on commercial diet and water 
discretionally. Ivermectin and levamisole used in this study 
were brought from Qian Kun Inc. (Chengdu, China).
Innoculation and treatment
As described by Papini and Casarosa [1], each mouse of all 
groups was infected orally with about 1,000 infective eggs. Mice 
were examined daily for clinical signs.
Mice were treated as follows:
Group A: ivermectin, by subcutaneous (SC) injection with 
0.3 mg/kg for 1 time, on day 3 post-infection (PI).
Group B: levamisole, by intramuscular (IM) injection with 8 
mg/kg for 1 time, on day 3 PI.
Group C: untreated controls (Control 1).
Group D: ivermectin, by SC injection with 0.3 mg/kg for 1 
time, on day 14 PI.
Group E: levamisole, by IM injection with 8 mg/kg for 1 time, 
on day 14 PI.
Group F: untreated controls (Control 2).
Larvae collection and procession
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day 13 PI, and processed respectively. For each carcass, the 
small and large intestines were removed, opened longitudinal-
ly, and rinsed vigorously in 3 changes of normal saline. As de-
scribed by Cho et al. [11], the intestinal wall, liver, lungs, and 
skeletal muscles, including bones, were separately minced with 
scissors and digested in artificial gastric juice (0.5% 1:10,000 
pepsin, 0.7% hydrochloric acid) for 2 hr at 37˚C along with 
vigorous agitation. B. transfuga larvae were recovered by Baer-
mann’s apparatus. Sediments were examined for larvae in a 
grid-marked glass by stereoscopic microscope (Olympus Inc., 
Tokyo, Japan). The brain was directly examined under a ste-
reoscopic microscope after squashing between 2 large glass 
slides [11]. Larvae recovered from brain, skeletal muscle, and 
internal organs (including liver, lungs, and intestinal wall) of 
each mouse were observed and counted using microscopic ex-
aminations. Counting apparatus were produced by Fujihira 
Inc. (Tokyo, Japan). Identically, mice of groups E-F were exam-
ined in the same way on day 24 PI, and the number of larvae 
recovered from them was also recorded. The percentage of effi-
cacy of the treatments was calculated from the count reduction 
of recovered larvae, using the arithmetic mean of larvae count 
with the following formula:
Efficacy (%)=100×(mean larvae recovered in controls-mean 
larvae recovered in treated mice)/ mean larvae recovered in 
controls
It is worth mentioning that larvae recovered from groups 
A-C and groups E-F represent migrating larvae and encapsulat-
ed larvae, respectively.
Data processing and statistical analysis
The number of larvae recovered was expressed as means± 
SD for each experimental group. Comparisons between exper-
imental groups were performed by Duncan’ multiple range us-
ing the statistical pack SPSS version 13.0 for Windows. The lev-
el of significance for analyses was set at P≤0.05 and ≤0.01.
RESULTS
Clinical symptoms
None of groups A and B mice displayed any clinical symp-
toms during the examination. Comparatively, clinical signs of 
verminous pneumonitis were obvious in 7 mice of group C, 
within day 4 PI. Mice of group C (n=4) showed mild clinical 
symptoms of nervous larvae migrans (NLM), which is caused 
by larvae migrating into the host brain, such as spinning 
around the longitudinal axis, continuous circling or lateral re-
cumbency, on day 10 PI.
Group D (n=3), group E (n=7), and group F (n=5) mice 
showed respiratory symptoms during the early stage of infec-
tion (days 0-4 PI). None of groups D and E mice appeared to 
have patent neurological symptoms, such as gait difficulty and 
circulatory movements until day 12 PI. It seemed that 6 mice 
with clinical NLM, which were treated with ivermectin in 
group D, failed to improve, but continued to deteriorate. Two 
out of 5 mice with neurological symptoms in group E took a 
favorable turn on day 17 PI, after having been treated with le-
vamisole.
Necropsy examination
During necropsy examination of groups A-C, several pin-
pointed grayish nodules and irregular petechial and ecchy-
motic hemorrhages were evident on the surfaces of the liver 
and lungs of group C mice. There existed no significant patho-
logical changes on the mice of groups A and B.
On the other hand, investigating the skeletal muscle and or-
gans of groups D-F, some encapsulating reactions were found 
to involve the intestinal wall and subcutaneous tissues of the 
neck, back, and legs, as well as the diaphragm. Obvious hem-
orrhagic foci and congestion were found on the surface of the 
brains of groups D-F. 
Number of larvae recovered and the efficacy of treatment
Mean numbers of larvae recovered from groups A-F are 
shown in Fig. 1. On one hand, comparing the mean total 
numbers of larvae recovered from 6 groups, respectively, it was 
easy to find out that there was no statistical difference between 
groups A and B, but the recovery in some groups was signifi-
cantly reduced (P<0.01) compared with that in group C. Sim-
ilarly, larval recovery in group D or E was strikingly reduced 
(P<0.01) from that in group F. However, the mean total num-
ber of larvae recovered from group D was remarkably lower 
than that from group E (P<0.01). In addition, there existed re-
markable differences (P<0.01) in total larval recovery, between 
groups A and D, as well as between group B and E. 
On the other hand, in different tissues and organs except 
the brain, it was also apparent that the larval recovery in treat-
ment groups was significantly reduced from that in control 
groups (P<0.01). Moreover, larval recovery from skeletal mus-
cles in groups A and D, groups B and E, and groups D and E 
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isted no significant differences between the 4 treatment groups 
in internal organs recovery. As for the larvae count in the brain, 
the difference between groups A and D was marked (P<0.05). 
However, the lack of difference in the brain recovery among 
groups D-F provided food for thought. 
The efficacy of the anthelmintics was estimated based on 
the % larvae reduction. As illustrated in Table 1, the total per-
centage reduction in larvae counts in mice following treatment 
with ivermectin in group A and levamisole in group B was 
88.3% and 81.1%, respectively. Similarly, it was 75.0% in 
group D (ivermectin) and 49.2% in group E (levamisole), re-
spectively.
Examined the matter from other angles, there was some-
thing valuable to be noticed. By comparison of the data of 2 
ivermectin groups, which were treated on different days PI, to-
tal percentage reduction in group A (88.3%) was higher than 
that in group D (75.0%). The same phenomenon existed in 
levamisole groups, as levamisole showed greatly higher effica-
cy in group B (81.1%) than in group E (49.2%).
On the other hand, for both group A (ivermectin-treating 
on day 3 PI) and group B (levamisole-treating on day 3 PI), in 
different organs, there were no significant differences in reduc-
tion percentage. In contrast, treatments conducted on day 14 
PI manifested the difference. Ivermectin administered in group 
D showed much lower larval reduction percentage in the brain 
(23.8%) than in other organs (79.9% in the intestinal organs 
and 76.9% in the skeletal muscle). For levamisole used in 
group E, reduction percentages in the brain and skeletal mus-
cle (24.9% and 33.5%, respectively) were much lower than 
that in intestinal organs (79.9%). It was remarkable that, in 
the brain, efficacy of treatments on day 14 PI (group D: 
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Table 1. Reduction in the number of larvae recovered in differ-
ent organs of treatment-group mice on days 13 and 24 PI
Treatment groups
Percentage (%) reduction in the number 
of larvae recovered from different organs  Total 
reduction
(%) 
Internal organs 
(lungs, liver and 
intestinal wall)
Brain Skeletal muscle
A (ivermectin, on
  day 13 PI)
84.1 76.5 92.4 88.3
B (levamisole, on 
  day 13 PI)
79.6 70.6 83.2 81.1
D (ivermectin, on 
  day 24 PI)
79.9 23.8 76.9 75.0
E (levamisole, on 
  day 24 PI)
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23.8%; group E: 42.9%) was much lower than those on day 3 
PI (group A: 76.5%; group B: 70.6%). 
DISCUSSION
The goal of this study was to compare the efficacy of iver-
mectin and levamisole for control of B. transfuga larvae in mice 
and whether ivermectin offered advantages to limit B. transfuga 
larval migrans in various organs, not only the brain.
The data demonstrated that ivermectin and levamisole were 
both useful in control of B. transfuga larvae in mice but at dif-
ferent rates. In addition, both of the 2 drugs were found to be 
more efficacious for migrating larvae than for encapsulated 
larvae. In the mass, ivermectin was superior to levamisole with 
regard to decreasing both free and encapsulated larvae. How-
ever, ivermectin had little effect on B. transfuga larvae invading 
into the brain. This result coincided with that obtained by Ka-
zacos [4]. Comfortably, our study showed that ivermectin was 
capable of reducing the larvae in other organs, including liver, 
lungs, intestinal wall, and muscle. Levamisole, on the other 
hand, showed steady qualities on control of visceral larva mi-
grans. However, it seemed to be failed to deal with larval gran-
ulomas in the skeletal muscle and brain.
As is known to all, administration of ivermectin via subcuta-
neous injection can achieve the greatest bioavailability. Due to 
its high lipophilic nature, ivermectin is extensively distributed 
in the organism. Moreover, its extremely low water solubility 
and its precipitation in subcutaneous tissues favours slow ab-
sorption from the injection site, leading to a long duration of 
activity [12]. In relative terms, administered by intramuscular 
injection, levamisole can distribute broadly as well, and be ab-
sorbed quickly, but fails to prolong presence in the blood 
stream. 
Ivermectin acts by binding to a glutamate-gated chloride 
channel receptor in nematode and arthropod nerve cells, and 
also increases the release of γ-aminobutyric acid (GABA) from 
synaptosomes of the nervous system and blocks the transmis-
sion of nervous stimuli to muscles resulting in flaccid paralysis 
of affected parasites, followed by their death or expulsion 
[13,14].
On the other hand, levamisole is agonists at nicotinic acetyl-
choline receptors of nematode muscles and cause spastic pa-
ralysis. However, it seems that levamisole can not kill larvae in 
tissues immediately, as well as adult worms. In normal times, 
after administration with levamisole, gastrointestinal nema-
todes expelled with feces are still alive. Furthermore, as an im-
munoregulatory agent, levamisole simulates the thymic hor-
mone thymopoietin, which probably targets at the stimulation 
of phagocytosis and regulatory T cells to restore homeostasis 
in a perturbed immune system [15]. So, there is every reason 
to believe that the efficacy of levamisole against larvae in the 
tissues, to a great extent, depends on the immunocompetence 
of the hosts. Comparatively speaking, the mechanism of ac-
tion of ivermectin may be more direct and effective. All the 
features of pharmacokinetic and mode of action which we 
mentioned above should successfully explain the difference 
between the 2 drugs in the efficacy against B. transfuga larvae. 
All previous treatment attempts of which the authors are 
aware indicate that ivermectin is unsuccessful in NLM treat-
ment, because in mammals ivermectin apparently is excluded 
from the CNS by the blood-brain barrier (BBB) [4,16]. The 
present study proved the viewpoint again, as the efficacy of 
ivermectin in the brain of groups A and D were only 76.5% 
and 23.8%, respectively. However, the significant difference 
between the 2 sets of data meant that it could markedly pre-
vent motile larvae from invading into the brain in the early 
stage of infection. The efficacy of levamisole in the brain of 
group E mice (42.9%), even though in a low level, was much 
higher than that of ivermectin in group D (23.8%). This phe-
nomenon conformed to the distribution of unbound levami-
sole in the anesthetized rat brains, as Lin and Tsai described 
[17]. It is indicated that levamisole should cross BBB more 
easily.
About 2 weeks later, larvae in tissues became encapsulated 
in well-circumscribed eosinophilic granulomas [4]. Yet, from 
the formation of granulomas in mouse tissues in response to 
trapped Schistosoma japonicum eggs, we may deduce that only 
within a few days PI, neutrophils should begin to infiltrate 
around the B. transfuga larvae, and inflammatory cells begin to 
infiltrate around and inside the lesions [18]. In the meantime, 
collagenous fibers are steadily generated by fibroblasts around 
the larvae. Finally, once the threat from larvae has been re-
duced or eliminated, the infiltrating population is reduced and 
the formation of scar tissues is induced, accompanied by the 
atrophy of micrangium around the granuloma. Maturation of 
granuloma ends in fibrosis. Drugs may hardly reach into the 
granuloma due to the atrophy of micrangium. In addition, 
tight and firm fibrosis which serves to wall off the granuloma 
contents [19], may block the infiltration of drugs. These may 
be the reason why the efficacy of both ivermectin and levomi-150   Korean J Parasitol Vol. 49, No. 2: 145-151, June 2011
sole against encapsulated larvae was much lower than that 
against migrating larvae.
In our experiment, we conducted culture of eggs, inocula-
tion, larvae collection and procession, and microscopic exami-
nation for counting larvae completely as previously described. 
However, the recovery in the controls were less than 4%. Sprent 
[20] administered 5,000 B. transfuga eggs to each of white 
mice and recovered around 7.8% of the larvae on day 14 PI. 
Papini et al. [8] orally infected chicken with about 5,000 em-
bryonated eggs of B. transfuga, and the recovery was 4.9% on 
day 15 PI. Cho et al. [11] inoculated 1,000 B. transfuga eggs 
into gerbils orally, and the recovery on day 14 PI was above 
12.5%. The differences among the larval recovery rates, on the 
one hand, may be attributed to susceptibility differences for 
various intermediate hosts, even for different strains of mice. 
Sugane and Oshima [21] orally infected 8 inbred strains of 
mice with 500 embryonated Toxocara canis eggs each. Different 
inbred strains of mice showed different larval recovery rates 
ranging from 9% to 24%. Therefore, it is assumed that differ-
ent strains of mice may be susceptible to B. transfuga in varying 
degrees. Certainly, further investigations would be needed to 
verify this hypothesis. On the other hand, it may be ascribed 
to different infectivity of eggs, which was correlated with 
length of time in cultures. Papini and Casarosa [22] demon-
strated that B. transfuga eggs reached infectivity after 2 weeks in 
cultures, peaked after 4 weeks, and then waned over the next 
18 months [22]. The eggs used in this experiment had been 
cultured for about 7 weeks before inoculated, and may be not 
the most infective. However, this did not affect the reliability 
of the results, because the same eggs were administered to 
treatment and control groups. The reduction % of larvae was 
still accuarate and reliable.
From what has discussed above, we may reasonably arrive at 
the conclusion that, in the absence of a completely effective 
larvicide, an early chemotherapy of using ivermectin or levam-
isole is feasible and useful in limiting the migratory activity of 
B. transfuga larvae, especially for migrating larvae. In addition, 
ivermectin is superior to levamisole, in the mass, with regard 
to decreasing both free and encapsulated larvae in mice.
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